$3.24
0.15% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US30049G1040
Symbol
EVOK
Sector
Industry

Evoke Pharma, Inc. Stock price

$3.24
+0.91 39.12% 1M
-1.32 28.95% 6M
-1.18 26.69% YTD
-2.40 42.54% 1Y
-33.65 91.22% 3Y
-286.20 98.88% 5Y
-800.28 99.60% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.00 0.15%
ISIN
US30049G1040
Symbol
EVOK
Sector
Industry

Key metrics

Market capitalization $4.84m
Enterprise Value $-2.64m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.68
EV/Sales (TTM) EV/Sales -0.23
P/S ratio (TTM) P/S ratio 0.42
P/B ratio (TTM) P/B ratio 0.83
Revenue growth (TTM) Revenue growth 89.89%
Revenue (TTM) Revenue $11.59m
EBIT (operating result TTM) EBIT $-5.00m
Free Cash Flow (TTM) Free Cash Flow $-3.88m
Cash position $12.62m
EPS (TTM) EPS $-3.18
P/S forward 0.31
EV/Sales forward negative
Short interest 1.86%
Show more

Is Evoke Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Evoke Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Evoke Pharma, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Evoke Pharma, Inc.:

Buy
100%

Financial data from Evoke Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
12 12
90% 90%
100%
- Direct Costs 0.31 0.31
29% 29%
3%
11 11
93% 93%
97%
- Selling and Administrative Expenses 16 16
30% 30%
141%
- Research and Development Expense - -
-
-
-5 -5
26% 26%
-43%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5 -5
26% 26%
-43%
Net Profit -5.08 -5.08
29% 29%
-44%

In millions USD.

Don't miss a Thing! We will send you all news about Evoke Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evoke Pharma, Inc. Stock News

Neutral
GlobeNewsWire
7 days ago
Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced financial results ...
Neutral
GlobeNewsWire
23 days ago
SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced that a new abstract comparing the incidence of tardive dyskinesia (TD) in patients receiving continuous versus intermittent oral metoclopramide (OMCP) treatment has be...
Neutral
Proactive Investors
26 days ago
Evoke PLC (LSE:EVOK) has kicked off 2025 with a steady start, reporting first-quarter revenue of £437.00 million—up 1% on last year and pretty much bang on with what it had guided. So far this year, revenue is up around 4%, and the company says it's still aiming for full-year growth in the 5-9% range.
More Evoke Pharma, Inc. News

Company Profile

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Head office United States
CEO Matthew D'Onofrio
Employees 3
Founded 2007
Website www.evokepharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today